Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura

We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in clinical remission until successful immunosuppression was achieved resulting in normal ADAMTS13 lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodgers, George M, Berndt, Misa, Fonteno, Megan, Gilreath, Jeffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987240/
https://www.ncbi.nlm.nih.gov/pubmed/36891167
http://dx.doi.org/10.2147/JBM.S395248
_version_ 1784901340283011072
author Rodgers, George M
Berndt, Misa
Fonteno, Megan
Gilreath, Jeffrey A
author_facet Rodgers, George M
Berndt, Misa
Fonteno, Megan
Gilreath, Jeffrey A
author_sort Rodgers, George M
collection PubMed
description We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in clinical remission until successful immunosuppression was achieved resulting in normal ADAMTS13 levels. This case illustrates the utility of caplacizumab therapy in treating refractory TTP.
format Online
Article
Text
id pubmed-9987240
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99872402023-03-07 Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura Rodgers, George M Berndt, Misa Fonteno, Megan Gilreath, Jeffrey A J Blood Med Case Report We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in clinical remission until successful immunosuppression was achieved resulting in normal ADAMTS13 levels. This case illustrates the utility of caplacizumab therapy in treating refractory TTP. Dove 2023-03-02 /pmc/articles/PMC9987240/ /pubmed/36891167 http://dx.doi.org/10.2147/JBM.S395248 Text en © 2023 Rodgers et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Rodgers, George M
Berndt, Misa
Fonteno, Megan
Gilreath, Jeffrey A
Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title_full Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title_fullStr Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title_full_unstemmed Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title_short Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
title_sort prolonged exposure to caplacizumab as rescue therapy in refractory immune thrombotic thrombocytopenic purpura
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987240/
https://www.ncbi.nlm.nih.gov/pubmed/36891167
http://dx.doi.org/10.2147/JBM.S395248
work_keys_str_mv AT rodgersgeorgem prolongedexposuretocaplacizumabasrescuetherapyinrefractoryimmunethromboticthrombocytopenicpurpura
AT berndtmisa prolongedexposuretocaplacizumabasrescuetherapyinrefractoryimmunethromboticthrombocytopenicpurpura
AT fontenomegan prolongedexposuretocaplacizumabasrescuetherapyinrefractoryimmunethromboticthrombocytopenicpurpura
AT gilreathjeffreya prolongedexposuretocaplacizumabasrescuetherapyinrefractoryimmunethromboticthrombocytopenicpurpura

Ejemplares similares